Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Chromosome 21

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Chromosome 21. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-021134-66 Sponsor Protocol Number: IJL-AFHT-TH10 Start Date*: Information not available in EudraCT
    Sponsor Name:Institut Jerome Lejeune
    Full Title: Efficacy assessment of systematic treatment with folinic acid and thyroid hormone on psychomotor development of Down Syndrome young children
    Medical condition: Down syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10044688 Trisomy 21 PT
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-003359-19 Sponsor Protocol Number: GALPED1001 Start Date*: 2007-08-07
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: An open-label study of two single oral doses of galantamine, examining the pharmacokinetics, safety, and tolerability in children with Down syndrome
    Medical condition: Children with Down syndrom
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013616 Down's syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000687-16 Sponsor Protocol Number: ARIDDS2 Start Date*: 2017-12-13
    Sponsor Name:AOU FEDERICO II
    Full Title: Novel avenues for the rescue of intellectual disability in Down syndrome
    Medical condition: DOWN SYNDROME
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10042801 Syndrome Down's LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008342-20 Sponsor Protocol Number: RAA08-015 Start Date*: 2009-02-23
    Sponsor Name:King's College London
    Full Title: Genetically determined brain abnormalities in Down’s Syndrome.- towards a treatment: A randomised, single-blind, placebo-controlled trial of lithium carbonate in Down’s Syndrome (DownsLit).
    Medical condition: Down's Syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-001263-23 Sponsor Protocol Number: BP27832 Start Date*: 2014-03-19
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY AND TOLERABILITY OF RO5186582 IN ADULTS AND ADOLESCENTS WITH DOWN SYNDROME (CLEMATIS)
    Medical condition: Down Syndrome
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10044688 Trisomy 21 PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-017775-19 Sponsor Protocol Number: CAMN107EIC01 Start Date*: 2010-05-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase IIIb, multicentre, open-label study of nilotinib in adult patients with newly diagnosed Philadelphia chromosome and/or BCR-ABL positive CML in chronic phase
    Medical condition: Newly diagnosed Philadelphia chromosome and/or BCR-ABL positive chronic myeloid leukaemia (CML) in chronic phase in adult patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10052065 Chronic phase chronic myeloid leukaemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) HU (Completed) ES (Completed) FI (Completed) GB (Completed) PT (Completed) DE (Completed) SE (Completed) CZ (Completed) DK (Completed) SK (Completed) GR (Completed) AT (Completed) LT (Completed) IT (Completed) LV (Completed) SI (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-022945-52 Sponsor Protocol Number: ADVL0516 Start Date*: 2012-01-26
    Sponsor Name:Children’s Oncology Group
    Full Title: A Phase 1 Study of BMS-354825 (Dasatinib) in Children with Recurrent/Refractory Solid Tumors or Imatinib Resistant Ph+ Leukemia.
    Medical condition: Refractory solid tumors Ph+ leukemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065252 Solid tumor LLT
    14.1 10022891 - Investigations 10034877 Philadelphia chromosome positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-001396-19 Sponsor Protocol Number: CSTI571 0109 Extension2 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: An extension to a phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome-positive leukemia including acute lymphoblastic leukaemia, acut...
    Medical condition: Philadelphia chromosome-opositive chronic myeloid leukamia in myeloid blast crisis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001564-21 Sponsor Protocol Number: GN09CP301 Start Date*: 2011-09-19
    Sponsor Name:NHS Greater Glasgow and Clyde [...]
    1. NHS Greater Glasgow and Clyde
    2. University of Glasgow
    Full Title: Towards Onset Prevention of COGnitive decline in adults with Down syndrome (the TOP-COG study)
    Medical condition: Alzheimer's disease Down syndrome
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.0 10010331 - Congenital, familial and genetic disorders 10013616 Down's syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-004230-40 Sponsor Protocol Number: B1871006 Start Date*: 2006-02-17
    Sponsor Name:Wyeth Pharmaceuticals Inc., a wholly owned subsidary of Pfizer Inc., 500 Arcola Road, Collegeville, PA 19426, USA
    Full Title: A Phase 1/2 Study of SKI-606 in Philadelphia Chromosme Positive Leukemias
    Medical condition: Philadelphia Chromosome positive leukemias occur as a result of a reciprocal translocation between chromosomes 9 and 22. Its most common phenotype is Chronic Myelogenous Leukemia (CML), which has ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10034877 Philadelphia chromosome positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) AT (Completed) FI (Completed) SE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001818-41 Sponsor Protocol Number: CAMN107A2109 Start Date*: 2006-01-04
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: Estudio abierto, multicéntrico de acceso expandido de AMN107 oral en pacientes adultos con Imatinib (Glivec®/Gleevec®) para leucemia mieloide crónica intolerante o resistente en crisis blástica o f...
    Medical condition: Leucemia mieloide crónica en fase acelerada, en crisis blástica y en fase crónica Chronic myeloid leukemia in blast crisis, accelerated phase or chronic phase
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GB (Completed) IE (Completed) CZ (Completed) SE (Completed) DK (Completed) BE (Completed) HU (Completed) AT (Completed) DE (Completed) PT (Prematurely Ended) GR (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004778-99 Sponsor Protocol Number: 120895 Start Date*: 2005-06-14
    Sponsor Name:Pediatric Unit, Hillerød Hospital
    Full Title: The growth of the internal genitalia and the bone mineralization during hormonal replacement therapy and the presence of aortic root dilatation in girls with Turner Syndrome
    Medical condition: Turner Syndrome is a common chromosomal abnormalities, characterized by one X-chromosome or a partial deletion in all or some cell-lines. The syndrome is known for features as short stature and abs...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000705-20 Sponsor Protocol Number: EsPhALL2017/COGAALL1631 Start Date*: 2017-12-11
    Sponsor Name:Università degli Studi Milano Bicocca
    Full Title: International phase 3 trial in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) testing imatinib in combination with two different cytotoxic chemotherapy backbones
    Medical condition: Philadelphia positive Acute Lumphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 10022891 - Investigations 10034877 Philadelphia chromosome positive PT
    21.0 100000004864 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing) IT (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) DE (Trial now transitioned) FI (Trial now transitioned) BE (Trial now transitioned) SE (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004680-39 Sponsor Protocol Number: AUTO3-PA1 Start Date*: 2017-06-21
    Sponsor Name:Autolus Limited
    Full Title: A Single Arm, Open-Label, Multi-Centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 in Paediatric and Adult Patients with R...
    Medical condition: Acute lymphoblastic leukaemia (ALL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    20.0 100000004864 10063625 Acute lymphoblastic leukemia recurrent LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-002517-36 Sponsor Protocol Number: CA180-015 Start Date*: 2004-12-27
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: A Phase II Study of BMS-354825 in Subjects with Lymphoid Blast Phase Chronic Myeloid Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib...
    Medical condition: Lympohid blast phase chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (ALL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Completed) FI (Completed) GB (Completed) DK (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000602-17 Sponsor Protocol Number: CABL001A2001B Start Date*: 2021-08-10
    Sponsor Name:Novartis Pharma AG
    Full Title: An open label, multi-center asciminib roll-over study to assess long-term safety in patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit fr...
    Medical condition: CML-CP (at the end of parent study) who are currently participating in an asciminb Novartis sponsored study (parent study)
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10009012 Chronic myelogenous leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) ES (Ongoing) DE (Ongoing) BG (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) AT (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-005987-94 Sponsor Protocol Number: GAHB-Study Start Date*: 2006-07-17
    Sponsor Name:University of Leipzig
    Full Title: Double-blind placebo-controlled randomised trial of lamivudine in the treatment of acute hepatitis B
    Medical condition: Acute Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059193 Acute hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003736-13 Sponsor Protocol Number: CCTL019B2205J Start Date*: 2017-09-29
    Sponsor Name:Novartis Pharmaceuticals
    Full Title: A Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute lymphoblastic leukemia
    Medical condition: Paediatric patients with B-cell acute lymphoblastic leukaemia and lymphoma who are refractory, relapsed to prior treatments
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-001691-39 Sponsor Protocol Number: UKM17_0023 Start Date*: 2019-07-16
    Sponsor Name:University Hospital Münster
    Full Title: LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma
    Medical condition: Lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) DE (Ongoing) DK (Trial now transitioned) IE (Completed) NO (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) CZ (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) NL (Ongoing) SK (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002260-33 Sponsor Protocol Number: CA180-226 Start Date*: 2009-02-16
    Sponsor Name:Bristol-Myers Squibb Internaltional Corporation
    Full Title: A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib Revised...
    Medical condition: Children and Adolescents with Newly Diagnosed Chronic Phase CML or with Ph+ Leukemias Resistant to or Intolerant to Imatinib
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10024324 Leukaemias HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed) ES (Ongoing) FR (Trial now transitioned) NL (Completed) GB (GB - no longer in EU/EEA) DE (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 09:01:19 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA